Noevir Holdings Co., Ltd.
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Dividend History 4Years Growth
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥230 | +2.2% |
| 2024 | ¥225 | +2.3% |
| 2023 | ¥220 | +2.3% |
| 2022 | ¥215 | +4.9% |
| 2021 | ¥205 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥61,143M | ¥62,552M | ¥63,823M | ¥64,724M |
| Gross Profit | ¥42,093M | ¥42,564M | ¥43,156M | ¥43,278M |
| Operating Income | ¥10,118M | ¥11,027M | ¥11,426M | ¥11,078M |
| Pretax Income | ¥10,118M | ¥11,027M | ¥11,426M | ¥11,078M |
| Net Income | ¥7,589M | ¥7,673M | ¥7,970M | ¥8,030M |
| EPS | ¥222.20 | ¥224.66 | ¥233.34 | - |
| Operating Margin | 16.55% | 17.63% | 17.90% | 17.12% |
| Balance Sheet | ||||
| Total Assets | ¥76,781M | ¥77,246M | ¥76,471M | ¥76,492M |
| Total Equity | ¥52,055M | ¥52,790M | ¥53,477M | ¥53,767M |
| Total Liabilities | ¥24,726M | ¥24,456M | ¥22,994M | ¥22,725M |
| Cash | ¥29,747M | ¥28,883M | ¥29,223M | ¥26,930M |
| Interest-bearing Debt | ¥1,005M | ¥914M | ¥828M | ¥742M |
| Equity Ratio | 67.80% | 68.34% | 69.93% | 70.29% |
| D/E Ratio | 0.02 | 0.02 | 0.02 | 0.01 |
| Cash Flow | ||||
| Operating CF | ¥5,845M | ¥7,624M | ¥9,123M | ¥7,928M |
| Investing CF | -¥255M | -¥3,544M | ¥1,525M | -¥2,417M |
| Financing CF | -¥7,380M | -¥7,493M | -¥7,712M | -¥7,924M |
| Free CF | ¥5,232M | ¥6,572M | ¥8,113M | ¥5,410M |
| Efficiency | ||||
| ROE | 14.58% | 14.53% | 14.90% | 14.93% |
| ROA | 9.88% | 9.93% | 10.42% | 10.50% |
Latest IR Information
-
No IR information found for this company.
Searched stock code: 4928
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥4,770
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Noevir Holdings Co., Ltd. develops, produces, and sells cosmetics, toiletries, medical supplies, and food products in China, Taiwan, South Korea, Hong Kong, Singapore, Thailand, the United States, and Canada. The company's Cosmetics segment develops, produces, and sells skincare products under various brands, including Noevir and Nameraka Honpo; excel make up line products and NOV hypoallergenic cosmetics, as well as provides contract manufacturing services for cosmetics and quasi drugs. Its Pharmaceutical and food business segment produces and sells Nanten Nodo Ame cough drops; functional drinks, such as the Min Min Da Ha; and over-the-counter pharmaceuticals comprising cold remedies, eye drops, and digestive aids, as well as nutritional supplements, and other products. The company's Other segment sells and leases apparel, body fashion, aircraft and ships, air transportation and pilot training business, etc. The company also provides market research. The company sells its products through drug stores and variety stores, and dermatology and medical institutions, as well as Noevir beauty studios and own retail stores. Noevir Holdings Co., Ltd. was founded in 1964 and is headquartered in Kobe, Japan.
